[go: up one dir, main page]

MD4596B1 - Pyrrolo[1,2,f][1,2,4]triazines useful for treating respiratory syncytial virus infections - Google Patents

Pyrrolo[1,2,f][1,2,4]triazines useful for treating respiratory syncytial virus infections Download PDF

Info

Publication number
MD4596B1
MD4596B1 MDA20160063A MD20160063A MD4596B1 MD 4596 B1 MD4596 B1 MD 4596B1 MD A20160063 A MDA20160063 A MD A20160063A MD 20160063 A MD20160063 A MD 20160063A MD 4596 B1 MD4596 B1 MD 4596B1
Authority
MD
Moldova
Prior art keywords
pyrrolo
virus infections
respiratory syncytial
syncytial virus
treating respiratory
Prior art date
Application number
MDA20160063A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD20160063A2 (en
MD4596C1 (en
Inventor
Майкл О'Нил Хенрехен Кларк
Эдвард Доуэрффлер
Ричард Л. Макман
Дастин Сиджел
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4596(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20160063A2 publication Critical patent/MD20160063A2/en
Publication of MD4596B1 publication Critical patent/MD4596B1/en
Publication of MD4596C1 publication Critical patent/MD4596C1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to substituted tetrahydrofuranyl-pyrrolo[1,2,f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as to formulations, methods of use and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.
MDA20160063A 2013-11-11 2014-11-06 Pyrrolo[1,2,f][1,2,4]triazines useful for treating respiratory syncytial virus infections MD4596C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11
PCT/US2014/064412 WO2015069939A1 (en) 2013-11-11 2014-11-06 Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections

Publications (3)

Publication Number Publication Date
MD20160063A2 MD20160063A2 (en) 2016-11-30
MD4596B1 true MD4596B1 (en) 2018-10-31
MD4596C1 MD4596C1 (en) 2019-05-31

Family

ID=52003049

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160063A MD4596C1 (en) 2013-11-11 2014-11-06 Pyrrolo[1,2,f][1,2,4]triazines useful for treating respiratory syncytial virus infections

Country Status (36)

Country Link
US (5) US9388208B2 (en)
EP (3) EP4122932A1 (en)
JP (7) JP6234571B2 (en)
KR (4) KR102355881B1 (en)
CN (3) CN114085243B (en)
AP (1) AP2016009186A0 (en)
AU (5) AU2014346665A1 (en)
BR (1) BR112016010261B1 (en)
CA (1) CA2928674C (en)
CL (1) CL2016001120A1 (en)
CR (1) CR20160220A (en)
CU (1) CU20160065A7 (en)
CY (1) CY1121948T1 (en)
DK (2) DK3068405T3 (en)
DO (1) DOP2016000107A (en)
EA (2) EA039734B1 (en)
ES (2) ES2743619T3 (en)
GT (1) GT201600086A (en)
HR (2) HRP20220920T1 (en)
HU (2) HUE044960T2 (en)
IL (1) IL245324B (en)
LT (2) LT3068405T (en)
MD (1) MD4596C1 (en)
MX (2) MX376186B (en)
MY (2) MY182986A (en)
NZ (1) NZ719592A (en)
PE (1) PE20160670A1 (en)
PH (1) PH12016500867A1 (en)
PL (2) PL3068405T3 (en)
PT (2) PT3505173T (en)
SG (1) SG11201603427XA (en)
SI (2) SI3505173T1 (en)
TR (1) TR201910961T4 (en)
UA (1) UA119050C2 (en)
WO (1) WO2015069939A1 (en)
ZA (1) ZA201603123B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596979B (en) 2009-09-21 2014-12-10 吉里德科学公司 Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
BR112013001553B1 (en) 2010-07-22 2021-01-12 Gilead Sciences, Inc. antiviral compounds for the treatment of paramyxoviridae infections and pharmaceutical compositions comprising them
UA119050C2 (en) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. PYROL [1.2-f] [1.2.4] TRIASINES USED FOR TREATMENT OF RESPIRATORY-SYNCITAL VIRAL INFECTIONS
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (en) 2014-07-28 2019-12-01 美商基利科學股份有限公司 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
JP6671355B2 (en) 2014-09-26 2020-03-25 リボサイエンス・エルエルシー 4'-Vinyl-substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication
TWI698444B (en) 2014-10-29 2020-07-11 美商基利科學股份有限公司 Methods for the preparation of ribosides
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
ES2918585T3 (en) 2015-09-16 2022-07-19 Gilead Sciences Inc Methods for treating Arenaviridae virus infections
US10953029B2 (en) 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JP6860585B2 (en) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク． Incorporation by reference of acyclic antiviral priority application
CN110869028B (en) 2017-03-14 2023-01-20 吉利德科学公司 Method of treating feline coronavirus infection
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
JP2020534361A (en) 2017-09-18 2020-11-26 ヤンセン・バイオファーマ・インコーポレイテッド Substituted nucleosides, nucleotides, and analogs thereof
CN109748921B (en) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-tert-butoxycarbonyl-protected heterocyclic compounds, methods for their preparation and methods for preparing C-nucleoside analogs
DK3706762T3 (en) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidine and derivatives and antiviral uses related thereto
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (en) * 2018-08-07 2024-03-15 中南大学 Method and system for preparing xanthate by slurry method
WO2020232194A1 (en) * 2019-05-14 2020-11-19 The Regents Of The University Of Michigan Methods for glycosylation
JP2023512656A (en) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド Methods for treating SARS CoV-2 infection
TWI883391B (en) * 2020-02-18 2025-05-11 美商基利科學股份有限公司 Antiviral compounds
CN118598916A (en) * 2020-02-18 2024-09-06 吉利德科学公司 Antiviral compounds
TWI775313B (en) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 Antiviral compounds
TWI884403B (en) * 2020-02-18 2025-05-21 美商基利科學股份有限公司 Antiviral compounds
CN111187269A (en) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 Synthetic method of Reidesciclovir intermediate
CN113336758B (en) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 Novel synthesis method of compound 7-iodopyrrolo [2, 1-f ] [1, 2, 4] triazin-4-amine
CN111233870A (en) * 2020-03-11 2020-06-05 中国科学技术大学 Method for rapidly preparing remdesivir pharmaceutical intermediates
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
JP7482250B2 (en) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (en) 2020-04-20 2025-05-30 中国科学院上海药物研究所 Application of nucleoside analogs or combination preparations containing nucleoside analogs in antiviral treatment
CN113527303B (en) * 2020-04-21 2022-06-10 浙江工业大学 Preparation process of Rudexivirin nucleus intermediate
CN111440176B (en) * 2020-04-28 2022-04-26 江苏大学 Metal complex promoted synthesis method of Reidesciclovir intermediate
PL4157272T3 (en) 2020-05-29 2025-10-20 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
CN111620903A (en) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-nucleoside analogue, preparation method and application of nitrile-containing C-nucleoside compound for synthesizing Rudexilvir
TWI819321B (en) 2020-06-24 2023-10-21 美商基利科學股份有限公司 1'-cyano nucleoside analogs and uses thereof
CN111732618A (en) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) Synthesis method of key fragments of Remdesivir
CN111793101B (en) * 2020-07-17 2022-09-30 四川大学 Process for the synthesis of C-nucleoside compounds
RS67481B1 (en) 2020-08-06 2025-12-31 Richter Gedeon Nyrt Remdesivir intermediates
WO2022046631A1 (en) 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202344257A (en) * 2020-10-16 2023-11-16 美商基利科學股份有限公司 Phospholipid compounds and uses thereof
CN113880846B (en) * 2020-12-31 2022-10-14 山东诚汇双达药业有限公司 Preparation method of 7-iodopyrrolo [2,1-F ] [1,2,4] triazin-4-amine
CN117120444A (en) * 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carboside using amides
JP7719954B2 (en) * 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド Phospholipid compounds and methods for producing and using same
AU2022331233A1 (en) 2021-08-20 2024-02-29 Shionogi & Co., Ltd. Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
TWI867455B (en) 2022-03-02 2024-12-21 美商基利科學股份有限公司 Compounds and methods for treatment of viral infections
EP4486455A1 (en) 2022-03-03 2025-01-08 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
IL315082A (en) * 2022-03-03 2024-10-01 Gilead Sciences Inc Antiviral compounds and methods of making and using the same
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (en) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (en) 1974-07-15 1977-07-20 Isf Spa APPARATUS FOR INHALATIONS
SE438261B (en) 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (en) 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ES2141108T3 (en) 1991-07-02 2000-03-16 Inhale Inc METHOD AND DEVICE FOR PROVIDING DRUGS IN AEROSOL.
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
EP2251015B1 (en) * 2000-10-18 2013-02-20 Gilead Pharmasset LLC Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
JP2005504087A (en) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (en) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd MORFOLINILO CONTAINING BENCIMIDAZOLS AS INHIBITORS OF THE REPLICATION OF RESPIRATORY SYNTHETIC VIRUSES
PT2114980E (en) * 2007-01-12 2012-09-25 Biocryst Pharm Inc Antiviral nucleoside analogs
ES2393038T3 (en) * 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Tretrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
ATE515861T1 (en) 2007-07-25 2011-07-15 Nokia Siemens Networks Oy METHOD FOR ADDRESSING ETHERNET STREAMS WITH STRUCTURED GPON GEM PORT ID
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EA201200525A1 (en) 2009-09-21 2012-09-28 Гайлид Сайэнсиз, Инк. 2'-FLUORINARY CARB-NUCLEOSIDE ANALOGUES FOR ANTI-VIRUS TREATMENT
CN102596979B (en) 2009-09-21 2014-12-10 吉里德科学公司 Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
WO2012012465A1 (en) * 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR112013001553B1 (en) * 2010-07-22 2021-01-12 Gilead Sciences, Inc. antiviral compounds for the treatment of paramyxoviridae infections and pharmaceutical compositions comprising them
TW201305185A (en) * 2010-09-13 2013-02-01 Gilead Sciences Inc 2'-fluoro substituted carbon-nucleoside analog for antiviral therapy
JP2013538230A (en) * 2010-09-20 2013-10-10 ギリアード サイエンシーズ， インコーポレイテッド 2'-Fluoro substituted carbanucleoside analogues for antiviral therapy
TW201306841A (en) 2010-12-20 2013-02-16 Gilead Sciences Inc Methods for treating HCV
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
GEP20166496B (en) * 2011-12-22 2016-06-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
PL2834258T3 (en) * 2012-03-13 2017-07-31 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
EA030189B8 (en) 2012-10-08 2018-10-31 Иденикс Фармасьютикалз Ллс 2'-chloro nucleoside analogs for hcv infection
TWI582077B (en) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses
UA119050C2 (en) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. PYROL [1.2-f] [1.2.4] TRIASINES USED FOR TREATMENT OF RESPIRATORY-SYNCITAL VIRAL INFECTIONS

Also Published As

Publication number Publication date
CN105899216A (en) 2016-08-24
CR20160220A (en) 2016-07-22
JP6393380B2 (en) 2018-09-19
EP4122932A1 (en) 2023-01-25
GT201600086A (en) 2018-01-17
EA029712B1 (en) 2018-05-31
US20250236623A1 (en) 2025-07-24
HUE059683T2 (en) 2022-12-28
PL3068405T3 (en) 2019-10-31
IL245324A0 (en) 2016-06-30
DOP2016000107A (en) 2016-06-15
MD20160063A2 (en) 2016-11-30
AU2023202506B2 (en) 2025-01-23
JP2021046413A (en) 2021-03-25
US20150133395A1 (en) 2015-05-14
JP2020055855A (en) 2020-04-09
US9701682B2 (en) 2017-07-11
KR20160074011A (en) 2016-06-27
CN114085243A (en) 2022-02-25
SI3068405T1 (en) 2019-08-30
KR20180059958A (en) 2018-06-05
KR102113705B1 (en) 2020-05-21
DK3068405T3 (en) 2019-07-29
EA201792639A1 (en) 2018-09-28
JP6234571B2 (en) 2017-11-22
SG11201603427XA (en) 2016-05-30
AU2023202506A1 (en) 2023-05-11
CN114085243B (en) 2024-04-26
JP2018070658A (en) 2018-05-10
US20190055253A1 (en) 2019-02-21
EP3505173B1 (en) 2022-07-06
PL3505173T3 (en) 2022-10-17
CL2016001120A1 (en) 2017-05-05
US10377761B2 (en) 2019-08-13
LT3068405T (en) 2019-08-12
AU2014346665A1 (en) 2016-05-19
CU20160065A7 (en) 2016-09-30
US20180016280A1 (en) 2018-01-18
HUE044960T2 (en) 2019-12-30
MD4596C1 (en) 2019-05-31
SI3505173T1 (en) 2022-09-30
AU2017232039B2 (en) 2019-03-28
HRP20220920T1 (en) 2022-10-28
JP2018021051A (en) 2018-02-08
MX2016006066A (en) 2016-08-12
AU2019204381B2 (en) 2021-04-01
UA119050C2 (en) 2019-04-25
JP2017502925A (en) 2017-01-26
CA2928674A1 (en) 2015-05-14
EP3505173A1 (en) 2019-07-03
US9388208B2 (en) 2016-07-12
AU2019204381A1 (en) 2019-07-11
EA201690978A1 (en) 2016-09-30
US20170008897A1 (en) 2017-01-12
ZA201603123B (en) 2019-08-28
AP2016009186A0 (en) 2016-04-30
TR201910961T4 (en) 2019-08-21
KR20200057103A (en) 2020-05-25
CN110003215A (en) 2019-07-12
AU2021201554A1 (en) 2021-04-01
KR102243724B1 (en) 2021-04-23
LT3505173T (en) 2022-10-10
KR20210046833A (en) 2021-04-28
EA039734B1 (en) 2022-03-04
PH12016500867A1 (en) 2016-06-20
AU2021201554B2 (en) 2023-02-02
US10059716B2 (en) 2018-08-28
HRP20191303T1 (en) 2019-10-18
CA2928674C (en) 2018-10-02
AU2017232039A1 (en) 2017-10-12
MX376186B (en) 2025-03-07
BR112016010261A2 (en) 2017-08-08
WO2015069939A1 (en) 2015-05-14
CN110003215B (en) 2021-12-17
BR112016010261B1 (en) 2022-02-08
JP7247155B2 (en) 2023-03-28
EP3068405B1 (en) 2019-05-01
CN105899216B (en) 2019-03-05
MY197933A (en) 2023-07-25
AU2017232039C1 (en) 2019-07-25
IL245324B (en) 2018-08-30
PE20160670A1 (en) 2016-07-10
EP3068405A1 (en) 2016-09-21
NZ719592A (en) 2017-12-22
KR102355881B1 (en) 2022-01-25
DK3505173T3 (en) 2022-08-22
JP2024041986A (en) 2024-03-27
JP2022088661A (en) 2022-06-14
MY182986A (en) 2021-02-05
KR101864973B1 (en) 2018-06-05
MX2020010628A (en) 2020-10-22
ES2926155T3 (en) 2022-10-24
JP7054394B2 (en) 2022-04-13
PT3068405T (en) 2019-08-05
CY1121948T1 (en) 2020-10-14
PT3505173T (en) 2022-11-18
ES2743619T3 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
MD4596B1 (en) Pyrrolo[1,2,f][1,2,4]triazines useful for treating respiratory syncytial virus infections
NZ727996A (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncytial virus infections
NZ728707A (en) 2’-chloro aminopyrimidinone and pyrimidine dione nucleosides
EA201791274A1 (en) PYRAZOLO [1,5-a] PYRIDIDIN DERIVATIVES SUBSTITUTED BY PYRAMIDINE WITH INHIBITING ACTIVITY AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
EA201300604A1 (en) COMPOUNDS INTENDED FOR THE TREATMENT OF RESPIRATORY-SYNCTIAL VIRAL INFECTIONS
HK1217492A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2016001855A (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection.
EA201692063A1 (en) UREA SPIRA COMPOUNDS AS ANTI-VIRUS COMPOUNDS AGAINST RSV
MX2014001510A (en) Anthranilamide compounds and their use as pesticides.
MX2014001604A (en) Anthranilamide compounds and their use as pesticides.
IN2012DN06678A (en)
MX2015000163A (en) Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection.
MX2014009933A (en) Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (rsv).
MX391523B (en) Intermediates and methods for synthesizing calicheamicin derivatives
MX2016001858A (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection.
MX2017003415A (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor.
NZ758580A (en) Pyrrolo[2,1-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
IN2013MU01219A (en)
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
MX2016009250A (en) Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection.

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees